Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand

Table 3 Serum bone turnover marker β-CTx (ng/mL) at baseline, at 26 weeks, and changes from baseline

β-CrossLaps (ng/mL)	Group I (N = 28)	Group II (N = 64)	Group III (N = 94)	Total (N = 186)
Baseline:
Mean (SD)	0.162 (0.102)	0.311 (0.205)	0.401 (0.205)	0.334 (0.210)
Baseline:
Min, Max	0.036, 0.483	0.050, 0.830	0.053, 1.270	0.036, 1.270
26 weeks:
Mean (SD)	0.121 (0.076)	0.106 (0.058)	0.077 (0.061)	0.094 (0.065)
26 weeks:
Min, Max	0.032, 0.319	0.032, 0.321	0.017, 0.477	0.017, 0.477
Percent reduction:
Mean (SD)	− 12.7 (56.9)	− 49.4 (35.5)	− 76.8 (20.2)	− 57.7 (40.3)
Min, Max	− 74.8, 165.8	− 92.8, 34.3	− 96.3, 27.7	− 96.3, 165.8
p value^a	0.0874	< 0.0001	< 0.0001	< 0.001

Group I: Recent/current bisphosphonate-, strontium-, estrogen-, or SERM-treated patients; Group II: Patients being treated with other drugs; Group III: Treatment-naïve patients; ^aβ-CTx levels at week 26 compared with baseline. 25(OH)D 25-hydroxyvitamin D, β-CTx Beta-CrossLaps, SERM selective receptor estrogen modulator

ISSN: 1471-2474